Current Status
Not Enrolled
Price
Free
Get Started
Course
Slides & Transcripts

Newborn Screening: From RUSP to Reality

To obtain CME/CE credit, you must LOG-IN and ENROLL (click orange button at top of page)

Jointly Provided by American Academy of CME and CheckRare CE

CheckRare
Supported by educational grants from bluebird bio Inc. and Ultragenyx Pharmaceutical Inc.

Start date: February 28, 2022
End date: February 28, 2023
Estimated time to complete: 0.25 hours

Activity Description

This is the first module in a four-part curriculum focused on Best Practices for Explaining Newborn Screening Results to Parents. This module will provide clinicians with the fundamentals of newborn screening.

Activity Faculty

Jerry Vockley, MD, PhD
Cleveland Family Endowed Chair in Pediatric Research, Professor of Human Genetics
Chief of Genetic and Genomic Medicine
University of Pittsburgh
Chief of Medical Genetics
Director of the Center for Rare Disease Research
UPMC Children’s Hospital of Pittsburgh

Target Audience

This activity has been designed to meet the educational needs of physicians specializing in obstetrics/gynecology, pediatrics, genetics, and family practice medicine. Other members of the care team may also participate.

After participating in the activity, learners should be better able to:

  • Explain how a disease becomes part of a NBS panel and why it helps patients

Accreditation and Credit Designation

In support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians

American Academy of CME, Inc., designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Statement

According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.

Disclosure of relevant financial relationships are as follows:

Faculty Educator

Dr. Vockley discloses the following relevant financial relationships with ineligible companies:

  • Advisory Board/Consultant: BioMarin Pharmaceutical, LogicBio Pharmaceuticals, Sangamo Therapeutics, Orphan Labs, Synlogic, Frictionless Solutions, American Gene Technologies International, Ecrol Capital, Sanofi, Axcella Health, Agios Pharmaceuticals, Applied Therapeutics
  • Shareholder: American Gene Technologies International, Axcella Health

Planners for this activity have no relevant financial relationships with any ineligible companies.

This activity will not review off-label or investigational information.

The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy, CheckRare CE, University of Pittsburgh or UPMC. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.

Method of Participation

There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you in within 30 days.

Hardware/Software Requirements

Windows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection

Macintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection

Privacy

For more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm. For more information about CheckRare’s privacy policy, please access https://checkrare.com/privacy/

Contact

For any questions, please contact: CEServices@academycme.org

Copyright

© 2022. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

Newborn Screening: From RUSP to Reality

Slides

Jointly Provided by American Academy of CME and CheckRare CE

CheckRare
Supported by educational grants from bluebird bio Inc. and Ultragenyx Pharmaceutical Inc.

Start date: February 28, 2022
End date: February 28, 2023
Estimated time to complete: 0.25 hours

Activity Description

This is the first module in a four-part curriculum focused on Best Practices for Explaining Newborn Screening Results to Parents. This module will provide clinicians with the fundamentals of newborn screening.

Activity Faculty

Jerry Vockley, MD, PhD
Cleveland Family Endowed Chair in Pediatric Research, Professor of Human Genetics
Chief of Genetic and Genomic Medicine
University of Pittsburgh
Chief of Medical Genetics
Director of the Center for Rare Disease Research
UPMC Children’s Hospital of Pittsburgh

Target Audience

This activity has been designed to meet the educational needs of physicians specializing in obstetrics/gynecology, pediatrics, genetics, and family practice medicine. Other members of the care team may also participate.

After participating in the activity, learners should be better able to:

  • Explain how a disease becomes part of a NBS panel and why it helps patients

Accreditation and Credit Designation

In support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians

American Academy of CME, Inc., designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Statement

According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.

Disclosure of relevant financial relationships are as follows:

Faculty Educator

Dr. Vockley discloses the following relevant financial relationships with ineligible companies:

  • Advisory Board/Consultant: BioMarin Pharmaceutical, LogicBio Pharmaceuticals, Sangamo Therapeutics, Orphan Labs, Synlogic, Frictionless Solutions, American Gene Technologies International, Ecrol Capital, Sanofi, Axcella Health, Agios Pharmaceuticals, Applied Therapeutics
  • Shareholder: American Gene Technologies International, Axcella Health

Planners for this activity have no relevant financial relationships with any ineligible companies.

This activity will not review off-label or investigational information.

The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy, CheckRare CE, University of Pittsburgh or UPMC. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.

Method of Participation

There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you in within 30 days.

Hardware/Software Requirements

Windows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection

Macintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection

Privacy

For more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm. For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/

Contact

For any questions, please contact: CEServices@academycme.org

Copyright

© 2022. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).